Galecto, Inc. announces the appointment of Bertil Lindmark as Chief Medical Officer per February 1, 2020. Dr. Lindmark, who joins from eTheRNA immunotherapies NV, has had an extensive and successful career in the pharmaceutical industry, building up broad clinical development and regulatory experience globally, and significant expertise in research and development in both large and small pharmaceutical organizations. As Global VP Clinical Development for the Respiratory and Inflammation franchises at AstraZeneca, Bertil Lindmark led development of Symbicort, one of the worlds’ leading respiratory brands, and many other respiratory and gastro-intestinal products. From 2010, he headed Global R&D at Almirall, involving 500 staff and the successful development and approval of several new drugs in the respiratory, gastro-intestinal, neuroscience and dermatological fields. In 2015 he joined ASLAN Pharmaceuticals in Singapore with a focus on cancer and atopic skin and lung diseases.